DARE — Dare Bioscience, Inc.
Is DARE overbought or oversold? Here is the current MarketMoodz read.
Dare Bioscience, Inc. (DARE) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.58. The rating moved from Oversold to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$0.58
- Last changeMoved from Oversold to Strong Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Dare Bioscience is a small, speculative biotech with modest public visibility and a valuation that reflects event‑driven upside and significant downside risk. Financial health is unclear from available materials; the company is likely capital‑constrained and could require financing that would dilute existing shareholders. Growth potential depends largely on clinical readouts, partnership/licensing activity, or successful commercialization of any approved assets. Current sector flows favor larger, defensive pharma names rather than micro‑cap development plays, reducing near‑term investor demand. Key risks include dilution, clinical/regulatory failure, low liquidity, and competitive pressures. Absent clear near‑term positive catalysts or transparent financial reporting, price action is expected to remain volatile and driven by binary news events.
Key factors
- Micro‑cap biotech with limited publicly available recent filings and constrained visibility into near‑term revenue streams
- Speculative clinical and product pipeline; material upside tied to any positive clinical readouts, partnerships, or licensing deals
- Sector environment favors large‑cap pharma and defensive healthcare flows, reducing relative investor interest in small, high‑volatility biotechs
- Ongoing industry trend toward convertible‑debt financings and potential dilution pressure for mid/small‑cap biotech issuers
- Low liquidity and elevated share‑price volatility typical of sub‑$1 biotechs, increasing execution risk for shareholders
- Any clinical/regulatory milestone or commercialization step could act as a sharp catalyst in either direction
Risks
- Need for near‑term capital raises leading to significant equity dilution
- Clinical trial setbacks or regulatory rejection for pipeline assets
- Competitive pressure from larger pharmaceutical companies with greater resources and established commercial channels
- Limited public disclosure and sparse sell‑side coverage increasing information asymmetry and investor uncertainty
- Market‑wide risk aversion to small biotech names if macro or funding conditions tighten
See today's live rating, score and targets
Members see the live hourly rating for DARE — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.